Top Markets
Coin of the day
Hemagen Diagnostics, Inc. Hemagen Diagnostics, Inc.

Hemagen Diagnostics, Inc.

HMGN
Rank in Stocks #42231
Hemagen Diagnostics, Inc., a global biotechnology firm, specializes in... Hemagen Diagnostics, Inc., a global biotechnology firm, specializes in delivering clinical diagnostic solutions for both human and animal health. The company designs, manufactures, and distributes the VIRGO product line, a series of human clinical immunoassays used for identifying autoimmune and infectious diseases, as well as acute phase proteins. Its comprehensive human diagnostic portfolio also encompasses Universal IFA components, various supplies, controls, calibrators, accessories, H-rotors, reagents, electrodes, equipment, and specialized assays covering conditions such as Chagas, acute phase proteins, and cytokines. For the veterinary market, Hemagen Diagnostics provides diagnostic equipment, reagents, consumables, accessories, and electrodes crucial for chemistry, hematology, and electrolyte analysis. The company reaches a diverse customer base, including laboratories, hospitals, and blood banks, through both direct sales and an extensive distribution network. Established in 1985, Hemagen Diagnostics maintains its headquarters in Columbia, Maryland.
Share Price
$0.0002
Last synced: 2026-08-11
Market Cap
$3.10K
Change (1 day)
0.00%
Change (1 year)
-98.67%
Country
US
Trade Hemagen Diagnostics, Inc. (HMGN)

Category

P/B ratio for Hemagen Diagnostics, Inc. (HMGN)
P/B ratio as of 2026 TTM: 0
According to Hemagen Diagnostics, Inc. latest financial reports and stock price the company's current price-to-book ratio (TTM) is 0. At the end of 2026 the company had a P/B ratio of 0.
P/B ratio history for Hemagen Diagnostics, Inc. from 2026 to 2026
P/B ratio at the end of each year
Year P/B Ratio Change
Not enough data for the provided dates.
P/B ratio for similar companies or competitors
Company P/B Ratio P/B Ratio Difference Country
6.2613 -
US
6.3483 -
NL
- -
CH
3.634 -
BE
- -
KR